No Impairment of Endothelial Function or Insulin Sensitivity with 4 Weeks of the HIV Protease Inhibitors Atazanavir or Lopinavir‐Ritonavir in Healthy Subjects without HIV Infection: A Placebo‐Controlled Trial | Zendy

Michael P. Dubé | Zendy; Changyu Shen | Zendy; Martha Greenwald | Zendy; Kieren J. Mather | Zendy

Open Access

No Impairment of Endothelial Function or Insulin Sensitivity with 4 Weeks of the HIV Protease Inhibitors Atazanavir or Lopinavir‐Ritonavir in Healthy Subjects without HIV Infection: A Placebo‐Controlled Trial

Author(s) -

Michael P. Dubé,

Changyu Shen,

Martha Greenwald,

Kieren J. Mather

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/590154

Subject(s) - lopinavir , ritonavir , medicine , atazanavir , dyslipidemia , endocrinology , placebo , insulin , vasodilation , endothelium , diabetes mellitus , immunology , human immunodeficiency virus (hiv) , viral load , pathology , alternative medicine , disease , covid-19 , antiretroviral therapy , infectious disease (medical specialty)

Dyslipidemia alone does not fully explain the increase in cardiovascular events among patients receiving protease inhibitor (PI)-based treatment for human immunodeficiency virus infection. Some PIs, such as indinavir, directly induce endothelial dysfunction, an effect that may mediate that portion of the increase in cardiovascular events that is not attributable to dyslipidemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research